Related Experiment Video
Updated: May 9, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Novel therapeutic agents for T-cell lymphomas.
Thomas Sau-Yan Chan1, Yok-Lam Kwong, Eric Tse
1Division of Haematology and Medical Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
Discovery Medicine
|August 6, 2013
Summary
Novel therapies offer hope for T-cell lymphomas, a challenging group of non-Hodgkin
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- T-cell lymphomas are diverse T-cell malignancies comprising 10-15% of non-Hodgkin's lymphoma.
- Current treatments, including chemotherapy and stem cell transplantation, show limited efficacy for many patients.
- Chemo-refractoriness and short remission durations pose significant challenges.
Purpose of the Study:
- To review novel therapeutic strategies for T-cell lymphomas.
- To explore potential improvements in disease control beyond conventional treatments.
Main Methods:
- Review of current literature on T-cell lymphoma treatments.
- Analysis of emerging therapeutic classes and their mechanisms.
- Focus on novel agents including monoclonal antibodies, epigenetic modifiers, newer cytotoxics, and targeted therapies.
Main Results:
- Conventional chemotherapy yields disappointing results for T-cell lymphomas.
- Stem cell transplantation is not suitable for all patients due to treatment resistance.
- Novel therapies demonstrate potential for enhanced disease control.
Conclusions:
- T-cell lymphoma treatment outcomes are generally poor with standard chemotherapy.
- Novel therapeutic approaches are crucial for improving patient outcomes.
- Targeted agents and immunotherapies represent promising avenues for future treatment strategies.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...